Audentes Therapeutics Inc (BOLD)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Audentes Therapeutics Inc (BOLD) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8011912
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月13日
◆ページ数:56
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Audentes Therapeutics Inc (Audentes) is a biotechnology company that focuses on the development and commercialization of gene therapy products for serious and life-threatening rare diseases. The company’s pipeline products include AT132, intended for the treatment of X-linked myotubular myopathy; AT982, for the treatment of Pompe disease; AT342, for the treatment of crigler-najjar syndrome; and AT307, for the treatment of CASQ2-related catecholaminergic polymorphic ventricular tachycardia. Audentes offers viral vectors for gene therapy most frequently and track record off AAV in non-pathogenic product, among others. The company has collaboration with various patient, research and medical communities to advance its product candidates. Audentes is headquartered in San Francisco, California, the US.

Audentes Therapeutics Inc (BOLD) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Audentes Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Audentes Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Audentes Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Audentes Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Audentes Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Audentes Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
Audentes Therapeutics Raises USD65 Million in Series C Financing Round 12
Audentes Therapeutics Raises USD42.5 Million in Series B Financing 15
Cardiogen Sciences Secures USD0.52 Million in Venture Funding 17
Audentes Therapeutics Raises US$30 Million In Series A Financing 18
Audentes Therapeutics Raises Funds through Seed Financing 20
Partnerships 21
Audentes Therapeutics Amends Co-Development with University of Pennsylvania 21
Audentes Therapeutics Enters Into Co-Development Agreement With Genethon For AT001 22
Licensing Agreements 23
Audentes Therapeutics Enters into Licensing Agreement with RegenxBio 23
Audentes Therapeutics Enters into Licensing Agreement with RegenxBio for CPVT 25
Cardiogen Sciences Enters into Licensing Agreement with Fondazione Salvatore Maugeri 27
Audentes Therapeutics Expands its Licensing Agreement with ReGenX Biosciences 28
Equity Offering 30
Audentes Therapeutics Files Registration Statement to Raise up to USD86.3 Million in Public Offering of Shares 30
Audentes Therapeutics Raises USD75 Million in IPO 31
Acquisition 32
Audentes Therapeutics Acquires Cardiogen Sciences 32
Audentes Therapeutics Inc – Key Competitors 33
Audentes Therapeutics Inc – Key Employees 34
Audentes Therapeutics Inc – Locations And Subsidiaries 35
Head Office 35
Other Locations & Subsidiaries 35
Recent Developments 36
Financial Announcements 36
Nov 14, 2017: Audentes Therapeutics Reports Third Quarter 2017 Financial Results and Provides Corporate Update 36
Aug 10, 2017: Audentes Therapeutics Reports Second Quarter 2017 Financial Results and Provides Corporate Update 38
May 11, 2017: Audentes Therapeutics Reports First Quarter 2017 Financial Results and Provides Corporate Update 40
Mar 09, 2017: Audentes Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update 42
Jan 09, 2017: Audentes Therapeutics Provides Full Year 2017 Strategic Outlook and Financial Guidance 45
Nov 10, 2016: Audentes Therapeutics Reports Third Quarter 2016 Financial Results and Provides Corporate Update 48
Aug 31, 2016: Audentes Therapeutics Reports Second Quarter 2016 Financial Results and Provides Corporate Update 49
Corporate Communications 51
Jun 13, 2017: Audentes Therapeutics Appoints Jennifer Jarrett to Board of Directors 51
May 08, 2017: Audentes Therapeutics Announces Appointment of John T. Gray, Ph.D. to Senior Vice President and Chief Scientific Officer 52
Dec 13, 2016: Audentes Therapeutics Appoints Julie Anne Smith to Board of Directors 53
Jan 05, 2016: Audentes Therapeutics Appoints Scott W. Morrison to Board of Directors 54
Other Significant Developments 55
Nov 29, 2016: Audentes Therapeutics Announces Initiation of Large-scale cGMP Production at its Gene Therapy Manufacturing Facility 55
Appendix 56
Methodology 56
About GlobalData 56
Contact Us 56
Disclaimer 56

List of Tables
Audentes Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Audentes Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Audentes Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Audentes Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Audentes Therapeutics Inc, Deals By Therapy Area, 2011 to YTD 2017 9
Audentes Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Audentes Therapeutics Raises USD65 Million in Series C Financing Round 12
Audentes Therapeutics Raises USD42.5 Million in Series B Financing 15
Cardiogen Sciences Secures USD0.52 Million in Venture Funding 17
Audentes Therapeutics Raises US$30 Million In Series A Financing 18
Audentes Therapeutics Raises Funds through Seed Financing 20
Audentes Therapeutics Amends Co-Development with University of Pennsylvania 21
Audentes Therapeutics Enters Into Co-Development Agreement With Genethon For AT001 22
Audentes Therapeutics Enters into Licensing Agreement with RegenxBio 23
Audentes Therapeutics Enters into Licensing Agreement with RegenxBio for CPVT 25
Cardiogen Sciences Enters into Licensing Agreement with Fondazione Salvatore Maugeri 27
Audentes Therapeutics Expands its Licensing Agreement with ReGenX Biosciences 28
Audentes Therapeutics Files Registration Statement to Raise up to USD86.3 Million in Public Offering of Shares 30
Audentes Therapeutics Raises USD75 Million in IPO 31
Audentes Therapeutics Acquires Cardiogen Sciences 32
Audentes Therapeutics Inc, Key Competitors 33
Audentes Therapeutics Inc, Key Employees 34
Audentes Therapeutics Inc, Subsidiaries 35

★海外企業調査レポート[Audentes Therapeutics Inc (BOLD)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Wockhardt Ltd (WOCKPHARMA):製薬・医療:M&Aディール及び事業提携情報
    Summary Wockhardt Ltd (Wockhardt) is a pharmaceutical company that manufactures and markets vaccines, active pharmaceutical ingredients, pharmaceutical and recombinant bio-pharmaceutical formulations. The company's product portfolio caters to various therapeutic areas including orthopedics, dental c …
  • AnaMar AB-製薬・医療分野:企業M&A・提携分析
    Summary AnaMar AB (AnaMar), a subsidiary of Koncentra Holding AB, discovers, develops and commercializes therapeutic strategies to treat debilitating inflammation, fibrosis and pain. The company develops drug candidates from several chemical classes that concentrates on the receptors and shows poten …
  • Ophthotech Corp (OPHT):企業の財務・戦略的SWOT分析
    Summary Ophthotech Corp (Ophthotech) is a biopharmaceutical company that develops novel therapeutics to treat ophthalmic diseases, with a focus on age-related and orphan retinal diseases. The company’s products include Zimura, a complement inhibitor for stargardt disease. It also provides Fovista, a …
  • Taisei Corporation:企業の戦略・SWOT・財務情報
    Taisei Corporation - Strategy, SWOT and Corporate Finance Report Summary Taisei Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Mologen AG (MGN):企業の財務・戦略的SWOT分析
    Summary Mologen AG (Mologen) is a biotechnology engaged in the development of novel drugs, immunotherapies and active ingredients. The company develops various pipeline products which include MGN1601, and others. It also engaged in developing EnanDIM product to treat antitumor efficacy by stimulatin …
  • Merz Aesthetics Inc:企業の戦略的SWOT分析
    Merz Aesthetics Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and se …
  • Diehl Defence Holding GmbH:企業の戦略的SWOT分析
    Diehl Defence Holding GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Fountain Biopharma Inc (4159):製薬・医療:M&Aディール及び事業提携情報
    Summary Fountain Biopharma Inc (Fountain Biopharma), a subsidiary of Microbio Co Ltd, is a developer of therapeutic monoclonal antibodies and DNA aptamers. The company’s technologies include IgE development platform, IEA’s drug development platform and tumor stem cell culture platform. Its IgE devel …
  • Agilvax Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Agilvax Inc (Agilvax) is a drug company that discovers and develops vaccines against infectious diseases and immunotherapies to treat cancer. The company develops products based on a proprietary virus-like particle platform technology. It develops immunotherapies to treat breast cancer, lung …
  • Crew Energy Inc (CR):石油・ガス:M&Aディール及び事業提携情報
    Summary Crew Energy Inc (Crew Energy) is an exploration and production company that offers our long-term production and development of crude oil and natural gas resources. The company offers exploration, development, strategic acquisitions, operations, management, and production programs. It operate …
  • Novartis AG (NOVN)-製薬・医療分野:企業M&A・提携分析
    Summary Novartis AG (Novartis) is a healthcare company that focuses on the discovery, development, manufacture and marketing of prescription and generic pharmaceutical products and eye care products. It provides drugs for the treatment of cancer, cardiovascular diseases, dermatological conditions, n …
  • LuLu Group International:企業の戦略・SWOT・財務情報
    LuLu Group International - Strategy, SWOT and Corporate Finance Report Summary LuLu Group International - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Merck & Co Inc (MRK):製薬・医療:M&Aディール及び事業提携情報
    Summary Merck & Co Inc (Merck) is a biopharmaceutical company that focuses on the discovery, development, manufacture and commercialization of prescription medicines, biologic therapies, vaccines and animal health products. It offers prescription products for treating cardiovascular, cancer, immune …
  • InFlectis BioScience:製薬・医療:M&Aディール及び事業提携情報
    Summary InFlectis BioScience (InFlectis) is a drug discovery company that identifies and develops small molecule drugs that target the unfolded protein response to treat misfolding protein disorders such as age-related and neurodegenerative diseases. The company’s pipeline products include IFB-088, …
  • San Miguel Power Association, Inc.:企業の戦略的SWOT分析
    San Miguel Power Association, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major …
  • Asahi Kasei Pharma Corp:製薬・医療:M&Aディール及び事業提携情報
    Summary Asahi Kasei Pharma Corp (Asahi Kasei Pharma), a subsidiary of Asahi Kasei Corp, discovers, develops, manufactures, and markets pharmaceuticals and diagnostic products. The company's portfolio encompasses prescription drugs, diagnostic reagents, and enzymes for diagnostic reagents. Its prescr …
  • Advanced Energy Industries, Inc. (AEIS)-エネルギー分野:企業M&A・提携分析
    Summary Advanced Energy Industries, Inc. (Advanced Energy) is a provider of power conversion, measurement and control solutions. The company designs, manufactures, sells, and supports power conversion products and solutions. These products are used in various applications ranging from manufacturing …
  • National Gypsum Co:企業の戦略・SWOT・財務分析
    National Gypsum Co - Strategy, SWOT and Corporate Finance Report Summary National Gypsum Co - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Allianz Insurance plc:企業の戦略・SWOT・財務情報
    Allianz Insurance plc - Strategy, SWOT and Corporate Finance Report Summary Allianz Insurance plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • CorEnergy Infrastructure Trust, Inc. (CORR)-石油・ガス分野:企業M&A・提携分析
    Summary CorEnergy Infrastructure Trust, Inc. (CorEnergy) is an energy infrastructure real estate investment trust. The company owns assets in the midstream and downstream US energy sectors that perform functions, such as pipelines, storage terminals, and transmission and distribution assets. Its por …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆